TNG News & Analysis

Tango Therapeutics R&D Head Sells $660,796 in Shares

Adam Crystal, the president of research and development at Tango Therapeutics, has sold shares worth $660,796. This financial move was disclosed in a recent filing. The sale could indicate a change in Crystal's personal financial strategy or views on the company's immediate prospects. Investors often scrutinize insider sales as they may imply projections about the company's performance. For Tango Therapeutics (TNG), understanding insider activity like this provides insight into potential future stock value changes.